Intensive Care Outcomes of Patients after High Dose Chemotherapy and Subsequent Autologous Stem Cell Transplantation: A Retrospective, Single Centre Analysis

• Main Authors: Panagiotis Karagiannis, Lena Sänger, Winfried Alsdorf, Katja Weisel, Walter Fiedler, Stefan Kluge, Dominic Wichmann, Carsten Bokemeyer, Valentin Fuhrmann
• Format: Article
• Language: English
• Published: MDPI AG 2020-06-01
• Series: Cancers
• Subjects: high dose chemotherapy; autologous stem cell transplantation; intensive care unit
• Online Access: https://www.mdpi.com/2072-6694/12/6/1678

High dose chemotherapy (HDT) followed by autologous peripheral blood stem cell transplantation (ASCT) is standard of care including a curative treatment option for several cancers. While much is known about the management of patients with allogenic SCT at the intensive care unit (ICU), data regarding incidence, clinical impact, and outcome of critical illness following ASCT are less reported. This study included 256 patients with different cancer entities. Median age was 56 years (interquartile ranges (IQR): 45–64), and 67% were male. One-year survival was 89%; 15 patients (6%) required treatment at the ICU following HDT. The main reason for ICU admission was septic shock (80%) with the predominant focus being the respiratory tract (53%). Three patients died, twelve recovered, and six (40%) were alive at one-year, resulting in an immediate treatment-related mortality of 1.2%. Independent risk factors for ICU admission were age (odds ratio (OR) 1.05; 95% confidence interval (CI) 1.00–1.09; <i>p</i> = 0.043), duration of aplasia (OR: 1.37; CI: 1.07–1.75; <i>p</i> = 0.013), and Charlson comorbidity score (OR: 1.64; CI: 1.20–2.23; <i>p</i> = 0.002). HDT followed by ASCT performed at an experienced centre is generally associated with a low risk for treatment related mortality. ICU treatment is warranted mainly due to infectious complications and has a strong positive impact on intermediate-term survival.